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We present the case of a 30 year-old man who was referred for evaluation of diffuse lymphadenopathy. Six weeks prior,
he noticed darkening of his urine associated with pale stools, nausea and an eventual 30 lb weight loss within a
month. The initial laboratory findings showed elevation of the liver enzymes. A CT scan showed mesenteric and
periaortic lymphadenopathy with the largest lymph node measuring 2.8 cm. Other laboratory results were otherwise
unremarkable (including a normal LDH) with the exception of positive serum antibodies against Epstein-Barr virus (EBV)
associated antigens (IgM+ and IgG+). An excisional biopsy of 4 of the small neck lymph nodes showed a normal
architecture with prominent follicles and an intact capsule. But, by immunohistochemistry two of the follicles showed
aberrant coexpression of BCL-2, in addition to CD10 and BCL-6. In-situ hybridization for early Epstein-Barr virus mRNA
(EBER) and immunohistochemistry for latent membrane protein-1 (LMP-1) stained both scattered positive cells, as well
as BCL-2 positive B-cells. Although an original diagnosis of in-situ follicular lymphoma was favored at an outside facility,
additional interphase fluorescence in situ hybridization (FISH) studies for t(14;18);(IGH-BCL2) rearrangement (performed
on the BCL-2 + follicles microdissected from the tissue block; Abott probe dual colour fusion) and molecular studies
(IGH gene rearrangement by PCR, also performed on the microdissected follicles) were negative. Serologic studies
(positive EBV antibodies) and immunostains in conjunction with the molecular studies confirmed the reactive nature of
the changes. Our case also shows direct immunopathogenic evidence of BCL-2 expression among the EBV-infected
cells, which has to our knowledge not been previously documented in vivo. A diagnosis of EBV infection should,
therefore, be considered when confronted with BCL-2 expression in germinal centers, particularly in younger
individuals, as the diagnosis of FLIS may lead to extensive and invasive haematologic work-ups.
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1323656318940068Case report
A 30 year-old man was referred for evaluation of diffuse
lymphadenopathy. 6 weeks prior, the patient noticed
darkening of his urine associated with pale stools, nausea
and an eventual 30 lb weight loss within a month. He also
complained of fever, myalgias, joint pain, and fatigue, which
occurred approximately 48 hours after the onset of the
urine colour changes. The initial laboratory results showed
elevation of liver enzymes (AST 278 Units/L, ALT 831
Units/L and total bilirubin of 1.9 mg/dl). The complete
blood count (CBC) included the following results: WBC 8.4* Correspondence: jfrater@path.wustl.edu
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reproduction in any medium, provided the or(neutrophils 54.5%, lymphocytes 34.3%, monocytes 7.8%,
eosinophils 2.5% and basophils 0.9%), Hgb 15.9, hematocrit
47.3, platelet count 151, LDH 179, RBC 5.12 MCV 92.5
and RDW 13.2. An abdominal ultrasound revealed a 2.9
cm mass within the pancreas and the liver. A follow-up CT
scan showed mesenteric and periaortic lymphadenopathy
with the largest lymph node measuring 2.8 cm. Two weeks
later, the majority of the symptoms resolved, but the patient
noticed new enlarged lymph nodes in the right neck and in
the left groin, measuring less than 1 cm. No associated
hepatosplenomegaly was identified. The patient's admission
laboratory results were otherwise unremarkable (including
a normal LDH) with the exception of positive serum. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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gens (IgM+ and IgG+).
An excisional biopsy of 4 of the small neck lymph
nodes showed a normal architecture with prominent fol-
licles (Figure 1) and an intact capsule. Two of the lymph
nodes appeared to have changes that were suggestive of
infarction and/or hemorrhage. In the subcapsular space
a group of larger cells with coarser chromatin and more
prominent nucleoli was seen. Immunohistochemistry
showed reactive appearing CD20-positive follicles with
interfollicular CD3-positive T-cells. Two of the follicles
showed aberrant coexpression of BCL-2, in addition to






Figure 1 Excisional (1st) biopsy from cervical lymph node. a and b – low
c – infarcted lymph node with occasional large cells with prominent nucleol
h – EBER and LMP-1.lymph nodes (Figure 2) showed similar morphologic
changes with approximately 3–4 additional follicles re-
vealing abnormal BCL-2 coexpression among the B-cells
with a germinal center phenotype. In-situ hybridization
for early Epstein-Barr virus mRNA (EBER) and immuno-
histochemistry for latent membrane protein-1 (LMP-1)
stained both scattered positive cells, as well as BCL-
2 positive B-cells. Although an original diagnosis of
in-situ follicular lymphoma was favored at an outside
facility, additional interphase fluorescence in situ
hybridization (FISH) studies for t(14;18);(IGH-BCL2)
rearrangement (performed on the BCL-2 + follicles







power view. Reactive appearing follicles with preserved architecture.
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Figure 2 Excisional (2nd) biopsy from inguinal lymph node. a – lymph node, second biopsy at low power showing similar morphologic
findings. b – CD3. c - CD20. d – BCL-2. e – BCL-6. f – CD10. The arrows indicate the abnormal phenotype in some of the follicles. g and h – FISH
using Vysis dual color-fusion probes for IGH-BCL-2 with no evidence of rearrangement.
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arrangement by PCR, also performed on the microdissected
follicles) were negative. Serologic studies (positive EBV
antibodies) and immunostains in conjunction with the
molecular studies confirmed the reactive nature of the
changes.
The patient's findings have completely resolved, and
there is no evidence of lymphoma after 9 months of
follow-up.
Discussion
This case represents an unusual presentation of infec-
tious mononucleosis with immunophenotypic findingssuggestive of in-situ follicular lymphoma. This observation
has not, to our knowledge, been previously reported in
the English-language medical literature. In 2002 Jaffe
et al. [1] described 25 patients with lymphadenopathy
having abnormal BCL-2 overexpression in follicle cen-
ters, associated with fairly preserved tissue architecture
and residual reactive germinal centers. The term in-situ
follicular lymphoma (FLIS) was coined to describe such
lesions, and was subsequently incorporated into the
World Health Organization classification of hematopoietic
neoplasms. A recent study showed that FLIS typically oc-
curs in the 5th or 6th decade of life, with only rare cases
reported in patients under 40 years of age. The follicular
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routinely demonstrated in the vast majority of the abnor-
mal follicles. Patients with FLIS were originally reported
as having a very low risk for developing overt follicular
lymphoma [2]. Others have suggested that FLIS indicates
a possible increased risk of several forms of lymphoid neo-
plasia, though many patients remain free of malignancy
after an extensive follow-up and staging [3,4]. The diagno-
sis of FLIS is typically an incidental finding, where lymph
nodes are biopsied secondary to reactive follicular hyper-
plasia or, sometimes, other pathology. To date, very little
attention has been paid to potential pathologic mimics of
FLIS, although some have shown that FLIS can be seen in
association with progressive transformation of germinal
centers [5,6].
Epstein-Barr virus (EBV) is a human herpesvirus with
an overall seroprevalence of >90% in all adults. It is
thought that in early infection, EBV-infected cells
undergo large-scale expansion within the germinal cen-
ters. However, the total number of EBV-positive cells even
in the acute phase of the disease is low, as previously
shown in germinal centers of tonsils from patients with
infectious mononucleosis. The EBV infected cells show
expression of BCL-6 and CD10, common germinal center
markers with variable staining for LMP-1, LMP-2 and
EBNA-1, which are EBV latent proteins. EBV also induces
upregulation and overexpression of BCL-2 among the B-
cells, findings commonly observed in latent EBV infection
but also in carcinomas which are EBV positve and EBV+
large B-cell lymphomas [7,8]. In addition, in experimen-
tal cell lines transfected with EBV, LMP-1 was capable
of NF-κβ activation leading to BCL-2 over-expression.
The EBV virus has a main pathogenic role in the devel-
opment of lymphoid and non-lymphoid malignancies
[9,10]. Several studies have shown its association with spe-
cific entities such as post-transplant lymphoproliferative
disorders of both B and T-cell lineage. Additionally, EBV
has a main role in the development of certain B-cell
lymphomas, such as endemic Burkitt's lymphoma, certain
types of classical Hodgkin lymphoma, EBV-positive diffuse
large B-cell lymphoma (DLCBL) of the elderly, DLBCL
associated with chronic inflammation and lymphomatoid
granulomatosis (among others). It is also related to T/NK
malignancies which include aggressive NK cell leu-
kemia, EBV-positive T-cell lymphoproliferative disor-
ders of childhood, extranodal NK/T-cell lymphoma and
angioimmunoblastic T-cell lymphomas [11].
The diagnosis of FLIS is most frequently made in
patients who are 50–60 years of age, and older than the
reported case. In addition, the serologic findings were
confirmatory for the diagnosis of infectious mononucle-
osis. Even though the immunophenotypic findings were
suggestive of FLIS, the absence of a t(14;18) rearrange-
ment, and the presence of EBER and LMP-1 expressionwere also helpful to exclude FLIS. Some authors have
also suggested that the pattern of intensity for CD10
(usually stronger in FLIS) can help distinguish FLIS from
other mimickers [12]. In our case, the CD10 intensity
was similar in both the BCL-2 coexpressing and non-
coexpressing follicles. Further, the patient developed no
subsequent lymphadenopathy and had complete reso-
lution of his symptoms. Our case also shows direct
immunopathogenic evidence of BCL-2 expression among
the EBV-infected cells, which has to our knowledge not
been previously documented in vivo. A diagnosis of
EBV infection should, therefore, be considered when
confronted with BCL-2 expression in germinal centers,
particularly in younger individuals, as the diagnosis of
FLIS may lead to extensive and invasive haematologic
work-ups.
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